1 December 2017 in OncoTargets and Therapy
MCMaría de Guadalupe Chávez-López
María de Guadalupe Chávez-López
EHElisabeth Hernández-Gallegos
Elisabeth Hernández-Gallegos
+3
Lung cancer is a major cause of cancer mortality. Thus, novel therapies are urgently needed. Repositioning of old drugs is gaining great interest in cancer treatment. Astemizole is an antihistamine proposed to be repositioned for cancer therapy. This drug targets several molecules involved in cancer including histamine receptors, ABC transporters and the potassium channels Eag1 and HERG. Astemizole inhibits the proliferation of different cancer cells including those from cervix, breast, leukemia and liver. Gefitinib is widely used to treat lung cancer; however, no response or drug resistance occurs in many cases. Here, we studied the combined effect of astemizole and gefitinib on the proliferation, survival, apoptosis and gene and protein expression of Eag1 channels in the human lung cancer cell lines A549 and NCI-H1975. Cell proliferation and survival were studied by the MTT method and the colony formation assay, respectively; apoptosis was investigated by flow cytometry. Gene expression was assessed by real-time polymerase chain reaction (RT-PCR), and protein expression was studied by Western blot analysis and immunocytochemistry. We obtained the inhibitory concentrations 20 and 50 (IC20 and IC50, respectively) values for each drug from the cell proliferation experiments. Drug combination at their IC20 had a superior effect by reducing cell proliferation and survival in up to 80% and 100%, respectively. The drugs alone did not affect apoptosis of H1975 cells, but the drug combination at their IC20 increased apoptosis roughly four times in comparison to the effect of the drugs alone. Eag1 mRNA levels and protein expression were decreased by the drug combination in A549 cells, and astemizole induced subcellular localization changes of the channel protein in these cells. Our in vitro studies strongly suggest that the combination astemizole–gefitinib may be a novel and promising therapy for lung cancer patients.
1 October 2021 in Nanoscience & Nanotechnology-Asia
The application of nanotechnology to stem cell research and development has made great strides during the last years. Nanotechnology offers a new opportunity for the research and development of stem cells. The mammary gland is a dynamic organ that undergoes extensive morphogenesis during the different stages of embryonic development, puberty, pregnancy, lactation and involution. There are multipotent stem cells that reside in mammary tissue (MaSCs) with the ability to self-renew and even differentiate into all types of mammary cells. To identify, characterize, and differentiate MaSCs, a variety of methods have been used to understand the signal transduction pathways that promote their self-renewal and their cellular fate. In the last decade, stem cell therapy has become a promising and modern topic of scientific research, which has raised great expectations. However, by itself, it presents some problems that have been overcome with the use of nanoparticles (NPs). A triple function has been accomplished: transport of drugs or biomolecules that help in the differentiation and proliferation of stem cells, cell targeting and contrast agents for real-time monitoring and obtaining bioimages for diagnostic and detection systems. The main objective of applying stem cells in conjunction with NPs is to control cellular activity, mainly the regenerative capacity of mammary tissue against diseases such as mastitis or to optimize milk production. In this review, we provide a current overview of the application of nanomaterials on stem cells, specifically bovine stem cells in both the mammary gland and milk, as they are a potential source of cell progenitors with potential characteristics and could be used in potential therapies based on these cells.